Additionally, sEVs from human cerebral ECs (hCEC) carrying abundant miR-214 could sensitize HCC cells towards oxaliplatin and sorafenib treatment through inhibition of splicing factor 3B subunit 3 (SF3B3) expression (79). This evidence concerns the gene SF3B3 and hepatocellular carcinoma.